Wall Street analysts expect that Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) will report earnings per share of $4.16 for the current quarter, Zacks reports. Seven analysts have provided estimates for Jazz Pharmaceuticals’ earnings. The lowest EPS estimate is $3.99 and the highest is $4.32. Jazz Pharmaceuticals posted earnings of $3.64 per share in the same quarter last year, which indicates a positive year over year growth rate of 14.3%. The business is expected to issue its next earnings report after the market closes on Tuesday, February 25th.

According to Zacks, analysts expect that Jazz Pharmaceuticals will report full year earnings of $15.95 per share for the current year, with EPS estimates ranging from $15.74 to $16.13. For the next year, analysts forecast that the business will report earnings of $17.33 per share, with EPS estimates ranging from $15.57 to $18.47. Zacks’ EPS calculations are a mean average based on a survey of research analysts that follow Jazz Pharmaceuticals.

A number of brokerages have recently issued reports on JAZZ. HC Wainwright reiterated a “hold” rating and set a $147.00 target price on shares of Jazz Pharmaceuticals in a report on Monday, November 11th. Barclays boosted their target price on Jazz Pharmaceuticals from $182.00 to $200.00 and gave the stock an “overweight” rating in a report on Monday, December 2nd. TheStreet upgraded Jazz Pharmaceuticals from a “c+” rating to a “b-” rating in a report on Friday, November 29th. Goldman Sachs Group began coverage on Jazz Pharmaceuticals in a report on Wednesday, January 8th. They set a “neutral” rating and a $153.00 target price for the company. Finally, BidaskClub cut Jazz Pharmaceuticals from a “sell” rating to a “strong sell” rating in a report on Thursday, February 6th. Two equities research analysts have rated the stock with a sell rating, seven have given a hold rating and eight have given a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and a consensus price target of $166.14.

In related news, EVP Michael Patrick Miller sold 1,500 shares of the business’s stock in a transaction that occurred on Thursday, February 13th. The stock was sold at an average price of $142.18, for a total transaction of $213,270.00. Following the transaction, the executive vice president now directly owns 26,571 shares of the company’s stock, valued at approximately $3,777,864.78. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Kenneth W. O’keefe sold 6,750 shares of the business’s stock in a transaction that occurred on Wednesday, December 4th. The stock was sold at an average price of $147.82, for a total value of $997,785.00. Following the transaction, the director now directly owns 5,644 shares in the company, valued at $834,296.08. The disclosure for this sale can be found here. Insiders have sold a total of 24,999 shares of company stock worth $3,714,896 over the last three months. 4.30% of the stock is currently owned by corporate insiders.

A number of institutional investors have recently added to or reduced their stakes in the stock. Renaissance Technologies LLC raised its position in shares of Jazz Pharmaceuticals by 13.8% in the 4th quarter. Renaissance Technologies LLC now owns 3,549,371 shares of the specialty pharmaceutical company’s stock valued at $529,850,000 after purchasing an additional 431,670 shares in the last quarter. AQR Capital Management LLC lifted its holdings in Jazz Pharmaceuticals by 47.5% during the 4th quarter. AQR Capital Management LLC now owns 1,966,252 shares of the specialty pharmaceutical company’s stock valued at $292,598,000 after buying an additional 633,022 shares in the last quarter. LSV Asset Management lifted its holdings in Jazz Pharmaceuticals by 8.4% during the 4th quarter. LSV Asset Management now owns 1,865,919 shares of the specialty pharmaceutical company’s stock valued at $278,544,000 after buying an additional 144,628 shares in the last quarter. State Street Corp lifted its holdings in Jazz Pharmaceuticals by 2.0% during the 4th quarter. State Street Corp now owns 1,471,245 shares of the specialty pharmaceutical company’s stock valued at $219,627,000 after buying an additional 29,446 shares in the last quarter. Finally, Boston Partners lifted its holdings in Jazz Pharmaceuticals by 1.8% during the 3rd quarter. Boston Partners now owns 1,364,882 shares of the specialty pharmaceutical company’s stock valued at $174,887,000 after buying an additional 23,859 shares in the last quarter. 89.15% of the stock is currently owned by hedge funds and other institutional investors.

Shares of NASDAQ:JAZZ traded down $1.08 during trading on Friday, reaching $140.85. 315,706 shares of the stock were exchanged, compared to its average volume of 465,099. The company has a debt-to-equity ratio of 0.56, a quick ratio of 3.71 and a current ratio of 3.89. Jazz Pharmaceuticals has a 12-month low of $116.52 and a 12-month high of $154.24. The firm has a market cap of $8.00 billion, a price-to-earnings ratio of 13.48, a price-to-earnings-growth ratio of 0.76 and a beta of 1.18. The firm’s 50-day moving average price is $146.52 and its 200 day moving average price is $137.40.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various unmet medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of sleep and hematology/oncology.

Recommended Story: Limitations of the P/E Growth ratio

Get a free copy of the Zacks research report on Jazz Pharmaceuticals (JAZZ)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Jazz Pharmaceuticals (NASDAQ:JAZZ)

Receive News & Ratings for Jazz Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.